The current Chair lost credibility with myself (and my confidence) when she chose to tenuously comment at the AGM in her address about "effective" spending to advance Bisantrene and a "clinically sound" August strategy. I did not see the point in making such assertions, particularly when it is quite obvious these are questionable - and given other directors have commented on clinical issues.
I mentioned the cash spend in quarterlies on consultants and through R&D looked heavy (particularly June and September 2023) by a few million.
Ann: Application for quotation of securities - RAC, page-26
-
- There are more pages in this discussion • 88 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add RAC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.44 |
Change
0.040(2.86%) |
Mkt cap ! $245.3M | |||
| Open | High | Low | Value | Volume |
| $1.45 | $1.49 | $1.41 | $101.7K | 69.88K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 9216 | $1.44 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.47 | 7767 | 2 |
View Market Depth
| Last trade - 16.10pm 09/08/2024 (20 minute delay) ? |
| RAC (ASX) Chart |